|
1
|
Enabling individualized therapy through nanotechnology.
|
Pharmacol Res
|
2010
|
1.28
|
|
2
|
Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases.
|
Trends Pharmacol Sci
|
2010
|
1.22
|
|
3
|
A low-voltage electrokinetic nanochannel drug delivery system.
|
Lab Chip
|
2011
|
0.99
|
|
4
|
A robust nanofluidic membrane with tunable zero-order release for implantable dose specific drug delivery.
|
Lab Chip
|
2010
|
0.99
|
|
5
|
Silicon micro- and nanofabrication for medicine.
|
Adv Healthc Mater
|
2013
|
0.90
|
|
6
|
Leveraging nanochannels for universal, zero-order drug delivery in vivo.
|
J Control Release
|
2013
|
0.89
|
|
7
|
Sustained zero-order release of intact ultra-stable drug-loaded liposomes from an implantable nanochannel delivery system.
|
Adv Healthc Mater
|
2013
|
0.86
|
|
8
|
Characterization of nanochannel delivery membrane systems for the sustained release of resveratrol and atorvastatin: new perspectives on promoting heart health.
|
Anal Bioanal Chem
|
2012
|
0.83
|
|
9
|
Delivering enhanced testosterone replacement therapy through nanochannels.
|
Adv Healthc Mater
|
2014
|
0.83
|
|
10
|
Characterization of a nanogland for the autotransplantation of human pancreatic islets.
|
Lab Chip
|
2013
|
0.82
|
|
11
|
Validated RP-HPLC method for the simultaneous analysis of gemcitabine and LY-364947 in liposomal formulations.
|
Curr Drug Targets
|
2013
|
0.80
|
|
12
|
Leveraging electrokinetics for the active control of dendritic fullerene-1 release across a nanochannel membrane.
|
Nanoscale
|
2015
|
0.78
|
|
13
|
Impedance characterization, degradation, and in vitro biocompatibility for platinum electrodes on BioMEMS.
|
Biomed Microdevices
|
2015
|
0.76
|
|
14
|
The Emerging Role of Nanotechnology in Cell and Organ Transplantation.
|
Transplantation
|
2016
|
0.75
|
|
15
|
Functional validation of an implantable medical dosing device by MRI at 3T.
|
Conf Proc IEEE Eng Med Biol Soc
|
2014
|
0.75
|
|
16
|
Differential scanning calorimetry as a tool to investigate the transfer of anticancer drugs to biomembrane model.
|
Curr Drug Targets
|
2013
|
0.75
|